{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:54:34Z","timestamp":1781790874008,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Informed by a community engagement process, we have developed a pragmatic, open-label, hybrid feasibility-implementation study of Group Psilocybin-Assisted Therapy (GPAT) for post-traumatic stress disorder (PTSD). As psychedelic-assisted therapies begin to enter the broader mental health arena, engaging communities in the design of research and care models is essential to ensuring that those most impacted have access to\u2014and trust in\u2014the treatments being developed. Guided by the principle of \u201cnothing about us without us,\u201d the proposed study was designed from the outset to be community-informed and co-designed. We established a tripartite collaborative partnership among researchers from the University of New Mexico (UNM) Department of Family &amp;amp; Community Medicine (DFCM) and the UNM Office for Community Health (OCH), the Bernalillo County Health Equity Council, and the national Psychedelic Mental Health Access (PMHA) Alliance. The protocol for the FDA-approved study uses a group therapy model incorporating peer facilitators with shared affinity with the participant group. There will be six groups of six participants, including veterans\/first responders and women survivors of sexual violence. The study is aligned with the New Mexico Therapeutic Psilocybin Program in its focus on access and equity, as well as the use of state-regulated whole psilocybin mushrooms rather than synthesized psilocybin. Each group will participate in two sessions using psilocybin mushroom-infused chocolates containing 20\u202fmg and 30\u202fmg of psilocybin, along with both group and individual therapy sessions. Outcomes will include safety and feasibility measures, as well as standard measures of PTSD, including the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). An extended integration model provides longer-term support to participants both within and beyond the clinical trial. A barrier to scaling psychedelic-assisted therapy is understanding what it actually costs to deliver a safe, comprehensive model of care, particularly for populations facing structural barriers to access. The University of California, Berkeley Collaborative for the Economics of Psychedelics (CEP) will conduct a prospective micro-costing study in parallel with GPAT. The analysis will capture delivery costs for community engagement, the group psilocybin therapy model, and the post-clinical protocol extended integration program.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Study protocol registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/clinicaltrials.gov\/study\/NCT07506395<\/jats:uri>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1845943","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:03Z","timestamp":1781671563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico"],"prefix":"10.3389","volume":"14","author":[{"given":"Lawrence","family":"Leeman","sequence":"first","affiliation":[{"name":"Department of Family and Community Medicine, School of Medicine, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, School of Medicine, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dara","family":"Menashi","sequence":"additional","affiliation":[{"name":"Psychedelic Mental Health Access Alliance","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanifa","family":"Nayo-Washington","sequence":"additional","affiliation":[{"name":"Psychedelic Mental Health Access Alliance","place":["Santa Fe, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Marseille","sequence":"additional","affiliation":[{"name":"Collaborative for the Economics of Psychedelics, University of California Berkeley","place":["Berkeley, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus","family":"Herrera","sequence":"additional","affiliation":[{"name":"Health Equity Council","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Romero","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, School of Medicine, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Page-Reeves","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, School of Medicine, University of New Mexico","place":["Albuquerque, NM, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref1","year":"2026"},{"key":"ref2","year":"2026"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder","volume":"9","author":"Bogenschutz","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1177\/02698811251362390","article-title":"Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: a nonrandomized open-label clinical trial","volume":"2025","author":"McGowan","year":"2025","journal-title":"J Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"ref6","year":""},{"key":"ref7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","article-title":"Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact","volume":"50","author":"Curran","year":"2012","journal-title":"Med Care"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1414969","DOI":"10.3389\/frhs.2024.1414969","article-title":"Editorial: hybrid effectiveness-implementation trial designs-critical assessments, innovative applications, and proposed advancements","volume":"4","author":"Kim","year":"2024","journal-title":"Front Health Serv"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2105\/ajph.93.8.1261","article-title":"Why don\u2019t we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition","volume":"93","author":"Glasgow","year":"2003","journal-title":"Am J Public Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/ajp.156.1.5","article-title":"Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research","volume":"156","author":"Wells","year":"1999","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/tbm\/ibae053","article-title":"Moving psychedelic-assisted therapies from promising research into routine clinical practice: lessons from the field of implementation science","volume":"14","author":"Adams","year":"2024","journal-title":"Transl Behav Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41562-025-02103-x","article-title":"Shrinking the know-do gap in psychedelic-assisted therapy","volume":"9","author":"Nicol","year":"2025","journal-title":"Nat Hum Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13011-020-00264-8","article-title":"PTSD and opioid use: implications for intervention and policy","volume":"15","author":"Dahlby","year":"2020","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s40501-020-00234-8","article-title":"PTSD \/ substance use disorder comorbidity: treatment options and public health needs","volume":"7","author":"Najavits","year":"2020","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/02698811211008567","article-title":"Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?","volume":"36","author":"Carhart-Harris","year":"2022","journal-title":"J Psychopharmacol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s40814-020-00634-w","article-title":"Guidance for conducting feasibility and pilot studies for implementation trials","volume":"6","author":"Pearson","year":"2020","journal-title":"Pilot Feasibility Stud"},{"key":"ref17","first-page":"1","article-title":"Community-based participatory research: assessing the evidence","volume":"99","author":"Viswanathan","year":"2004","journal-title":"Evid Rep Technol Assess"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1556\/2054.2025.00394","article-title":"A primer for culturally attuned psychedelic clinical trials","volume":"9","author":"Ching","year":"2025","journal-title":"J Psychedelics Stud"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e842","DOI":"10.1097\/HS9.0000000000000842","article-title":"A lack of diversity, equity, and inclusion in clinical research has direct impact on patient care","volume":"7","author":"El-Galaly","year":"2023","journal-title":"HemaSphere"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10464-009-9227-y","article-title":"Multilevel community-based culturally situated interventions and community impact: an ecological perspective","volume":"43","author":"Trickett","year":"2009","journal-title":"Am J Community Psychol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7932","DOI":"10.20935\/MHealthWellB7932","article-title":"Dignity is the method: ethnic minority mental health, structural harm, and the constellation model","volume":"2","author":"Kar","year":"2025","journal-title":"Acad Ment Health Well Being"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"eClin Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1556\/2054.2026.00485","article-title":"Low-income group psilocybin assisted therapy for depression: an Oregon feasibility study","volume":"2026","author":"Hicks","year":"2026","journal-title":"J Psychedelics Stud"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"863552","DOI":"10.3389\/fpsyt.2022.863552","article-title":"Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders","volume":"13","author":"Oehen","year":"2022","journal-title":"Front Psych"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","article-title":"Psychedelic-assisted group therapy: a systematic review","volume":"51","author":"Trope","year":"2019","journal-title":"J Psychoactive Drugs"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with Cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J Pain Symptom Manag"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2023.0351","article-title":"Assessment of psilocybin therapy for patients with Cancer and major depression disorder","volume":"9","author":"Agrawal","year":"2023","journal-title":"JAMA Oncol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1293243","DOI":"10.3389\/fpsyt.2023.1293243","article-title":"Group psychedelic therapy: empirical estimates of cost-savings and improved access","volume":"14","author":"Marseille","year":"2023","journal-title":"Front Psych"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s10597-015-9982-1","article-title":"Peer support and outcome for veterans with posttraumatic stress disorder (PTSD) in a residential rehabilitation program","volume":"52","author":"Jain","year":"2016","journal-title":"Community Ment Health J"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/fampra\/cmac004","article-title":"The benefits and challenges of established peer support programmes for patients, informal caregivers, and healthcare providers","volume":"39","author":"Joo","year":"2022","journal-title":"Fam Pract"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/birt.12814","article-title":"Peer support and mobile health for perinatal mental health: a scoping review","volume":"51","author":"Liblub","year":"2024","journal-title":"Birth (Berkeley, Calif)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/NMD.0000000000000635","article-title":"Group psychotherapeutic factors and perceived social support among veterans with PTSD symptoms","volume":"205","author":"Cox","year":"2017","journal-title":"J Nerv Ment Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2512680","DOI":"10.1080\/20008066.2025.2512680","article-title":"Role of peer support in mitigating PTSD and suicide risk among firefighters experiencing colleagues\u2019 death","volume":"16","author":"Kim","year":"2025","journal-title":"Eur J Psychotraumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1017\/S1478951524001688","article-title":"Cosmology of belonging: the role of community in the therapeutic use of psychedelics","volume":"23","author":"Dorsen","year":"2025","journal-title":"Palliat Support Care"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanist Psychol"},{"key":"ref36","year":""},{"key":"ref37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/ph18070989","article-title":"Chemical composition and biological activities of Psilocybe mushrooms: gaps and perspectives","volume":"18","author":"Luz","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1038\/s41380-024-02477-w","article-title":"Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain","volume":"29","author":"Shahar","year":"2024","journal-title":"Mol Psychiatry"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41598-026-39483-7","article-title":"Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain","volume":"16","author":"Murray","year":"2026","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1556\/2054.2024.00379","article-title":"\u201cThe mushroom was more alive and vibrant\u201d: patient reports of synthetic versus organic forms of psilocybin","volume":"8","author":"Kryskow","year":"2024","journal-title":"J Psychedelics Stud"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"824077","DOI":"10.3389\/fpsyg.2022.824077","article-title":"Psychedelic integration: an analysis of the concept and its practice","volume":"13","author":"Bathje","year":"2022","journal-title":"Front Psychol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan","year":"2023","journal-title":"J Psychopharmacol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology: official publication of the American college of","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12152-023-09536-z","article-title":"When the trial ends: the case for post-trial provisions in clinical psychedelic research","volume":"17","author":"Jacobs","year":"2024","journal-title":"Neuroethics"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1037\/ser0000269","article-title":"Peer support in an outpatient program for veterans with posttraumatic stress disorder: translating participant experiences into a recovery model","volume":"16","author":"Kumar","year":"2019","journal-title":"Psychol Serv"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1080\/00223891.1990.9674095","article-title":"Psychometric characteristics of the multidimensional scale of perceived social support","volume":"55","author":"Zimet","year":"1990","journal-title":"J Pers Assess"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1845943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:31:56Z","timestamp":1781789516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1845943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2026.1845943"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1845943","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1845943"}}